WCLC 2022 | The rationale behind targeting Aurora A Kinase in lung cancer

Jong Woo Lee, MD, PhD, Yale Cancer Center and Yale University School of Medicine, New Haven, CT, provides the rationale behind targeting Aurora A Kinase (ARUKA) in lung cancer. ARUKA has been shown to be highly expressed in lung cancer, the expression of which is associated with poor patient outcomes. Additionally, ARUKA has been implicated in acquired resistance to targeted therapy, including to treatments targeting KRASG12C such as sotorasib. Thus, targeting ARUKA may aid in overcoming resistance to such targeted agents. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.